Next-Generation Cancer Diagnostics: Technologies and Global Markets

April 28, 2011

Wellesley, Mass. – According to a new technical market research report, NEXT-GENERATION CANCER DIAGNOSTICS: TECHNOLOGIES AND GLOBAL MARKETS (BIO081A) from BCC Research (www.bccresearch.com), the global market value for next-generation cancer diagnostics was an estimated $776 million in 2010, but is expected to increase to more than $5.3 billion in 2015, for a 5-year compound annual growth rate (CAGR) of 47%.

The largest segment of the market, genomic analysis, had an estimated value of $703 million in 2010 and is expected to increase at a CAGR of 38.2% to reach more than $3.5 billion in 2015.

The second-largest segment, proteomic analysis, is projected to reach $861 million in 2015, after rising at a hefty CAGR of 81.3% from its estimated value of $43.9 million in 2010.

The epigenomic analysis segment also will rise steeply, at a CAGR of 102.6%, from $18 million in 2010 to $614 million in 2015.

The cellular analysis segment is projected to increase at a CAGR of 95.4% to reach $296.1 million in 2015. It was valued at only $10.4 million in 2010.

The objective of this report is to review the status of next-generation cancer diagnostic technologies and assays, and assess their worldwide growth potential over a 5-year period. BCC is particularly interested in characterizing the markets for the key next-generation platforms: real-time polymerase chain reaction (RT-PCR), DNA microarrays, lab-on-a-chip (LOAC), protein microarrays, circulating tumor cells (CTCs), and multiplexed conventional and next-generation sequencing.

A primary focus of this report is genomic, epigenomic, proteomic, and cellular analysis in which the majority of cancer diagnostics sales occur.

The next-generation cancer diagnostics industry is currently a small but growing segment of the in vitro diagnostics industry. Some tests are established already, for example, in cervical cancer screening or breast cancer prognostics. A significant number of new assays using innovative platforms are in the diagnostic pipeline. For companies seeking to exploit the growth in this industry, it is important to understand the various next-generation platforms and the  developmental status for each cancer indication. 

This study will be of particular interest to companies in the following industries:  in vitro diagnostics, pharmaceuticals, biotechnology, nanomaterials, life sciences tools and reagents, medical devices, DNA sequencing, DNA microarrays, protein microarrys, biochips, lab-on-a-chip, PCR, clinical laboratories, and bioinformatics.

To Contact us, click here  

Next-Generation Cancer Diagnostics: Technologies and Global Markets( BIO081A )
Publish Date: Apr 2011    

Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email press@bccresearch.com or visit www.bccresearch.com/media to request access to our library of market research.